Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

被引：0
|
作者：
Nobuaki Suzuki
Shoichi Hazama
Takeshi Nagasaka
Hiroaki Tanioka
Yasuo Iwamoto
Yuji Negoro
Masami Yamauchi
Michiya Kobayashi
Hiroshi Okuda
Noriaki Fujishima
Taku Nishimura
Naoki Yamanaka
Kazuhiro Toyota
Yoshiko Mori
Yuki Nakagami
Mototsugu Shimokawa
Hiroaki Nagano
Masazumi Okajima
机构：
[1] Yamaguchi University Graduate School of Medicine,Department of Gastroenterological, Breast and Endocrine Surgery
[2] Yamaguchi University School of Medicine,Department of Translational Research and Developmental Therapeutics Against Cancer
[3] Kawasaki Medical School,Department of Clinical Oncology
[4] Hiroshima City Hiroshima Citizens Hospital,Department of Medical Oncology
[5] Kochi Health Sciences Center,Department of Medical Oncology
[6] Hiroshima Prefectural Hospital,Division of Clinical Oncology
[7] Kochi Medical School Hospital,Cancer Treatment Center
[8] Onomichi General Hospital,Surgery and Endoscopic Surgery
[9] Fukuda Clinic of Internal Medicine,Department of Surgery
[10] Heart and Digestive,Department of Surgery
[11] Kokura Memorial Hospital,Department of Surgery
[12] Japanese Red Cross Yamaguchi Hospital,Department of Surgery
[13] National Hospital Organization Higashihiroshima Medical Center,Department of Gastroenterological Surgery
[14] Okayama University Graduate School of Medicine,Cancer Biostatistics Laboratory, Clinical Research Institute
[15] Dentistry and Pharmaceutical Sciences,Department of Surgery
[16] National Kyushu Cancer Center,undefined
[17] Hiroshima City Hiroshima Citizens Hospital,undefined
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Bevacizumab; CAPIRI; Biweekly; Second line; mCRC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1223 / 1230
页数：7
相关论文
共 50 条
  • [21] Preliminary results of bevacizumab plus raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): A multicenter phase II trial
    Li, S.
    Zhu, L.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S723 - S723
  • [22] Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
    Sun, Yongkun
    Zhang, Jing
    Wu, Guifu
    Zhong, Xiaomin
    Zhang, Wen
    Liang, Ping
    Li, Baoqi
    Cui, Chengxu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 155 - 155
  • [23] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
    Li, Sheng
    Li, Xiaoyou
    Zhu, Qianni
    Gao, Jin
    Zhu, Chunrong
    Zhu, Liangjun
    CANCER CONTROL, 2024, 31
  • [24] Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: Results of second-line therapy
    Kawakami, Kentaro
    Kito, Yosuke
    Mitani, Seiichiro
    Hino, Kaori
    Izawa, Naoki
    Hanamura, Fumiyasu
    Yamamoto, Yoshiyuki
    Shoji, Hirokazu
    Komori, Azusa
    Boku, Shogen
    Tsuchihashi, Kenji
    Baba, Eishi
    Kato, Kyoko
    Nonagase, Yoshikane
    Matsumoto, Toshihiko
    Furuta, Mitsuhiro
    Kawakami, Hisato
    ANNALS OF ONCOLOGY, 2023, 34 : S1406 - S1407
  • [25] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
  • [26] A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
    Puthillath, Ajithkumar
    Mashtare, Terry, Jr.
    Wilding, Gregory
    Khushalani, Nikhil
    Steinbrenner, Lynn
    Ross, Mary Ellen
    Romano, Karen
    Wisniewski, Michelle
    Fakih, Marwan G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (03) : 242 - 248
  • [27] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Yosuke Horita
    Yasuhide Yamada
    Ken Kato
    Yoshinori Hirashima
    Kouhei Akiyoshi
    Kengo Nagashima
    Takako Nakajima
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    International Journal of Clinical Oncology, 2012, 17 : 604 - 609
  • [28] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Horita, Yosuke
    Yamada, Yasuhide
    Kato, Ken
    Hirashima, Yoshinori
    Akiyoshi, Kouhei
    Nagashima, Kengo
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609
  • [29] FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
    Iwamoto, S.
    Takahashi, T.
    Tamagawa, H.
    Nakamura, M.
    Munemoto, Y.
    Kato, T.
    Hata, T.
    Denda, T.
    Morita, Y.
    Inukai, M.
    Kunieda, K.
    Nagata, N.
    Kurachi, K.
    Ina, K.
    Ooshiro, M.
    Shimoyama, T.
    Baba, H.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1427 - 1433
  • [30] Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
    Ishizaki, Tetsuo
    Mazaki, Junichi
    Enomoto, Masanobu
    Shigoka, Masatoshi
    Kasahara, Kenta
    Matsudo, Takaaki
    Kawakita, Hideaki
    Nagakawa, Yuichi
    Katsumata, Kenji
    Tsuchida, Akihiko
    ANTICANCER RESEARCH, 2021, 41 (04) : 2157 - 2163
12345